Calithera Biosciences, Inc. (CALA) Receives Average Rating of “Hold” from Analysts
Calithera Biosciences, Inc. (NASDAQ:CALA) has received an average rating of “Hold” from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $14.40.
A number of equities research analysts have recently weighed in on the stock. BidaskClub lowered shares of Calithera Biosciences from a “sell” rating to a “strong sell” rating in a report on Saturday, August 12th. HC Wainwright restated a “buy” rating and issued a $19.00 price objective (up from $14.00) on shares of Calithera Biosciences in a report on Monday, June 12th. Zacks Investment Research lowered shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a report on Thursday, July 13th. Finally, Wells Fargo & Company restated an “outperform” rating and issued a $20.00 price objective (up from $15.00) on shares of Calithera Biosciences in a report on Tuesday, June 6th.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/09/16/calithera-biosciences-inc-cala-receives-average-rating-of-hold-from-analysts.html.
In other Calithera Biosciences news, VP Keith Orford sold 2,120 shares of the firm’s stock in a transaction on Monday, July 17th. The shares were sold at an average price of $18.31, for a total transaction of $38,817.20. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 16.30% of the company’s stock.
A number of institutional investors have recently modified their holdings of CALA. Nationwide Fund Advisors purchased a new position in Calithera Biosciences during the 1st quarter worth $131,000. Acadian Asset Management LLC purchased a new stake in shares of Calithera Biosciences in the first quarter valued at about $381,000. Bank of New York Mellon Corp boosted its holdings in shares of Calithera Biosciences by 17.5% in the first quarter. Bank of New York Mellon Corp now owns 32,688 shares of the biotechnology company’s stock valued at $377,000 after acquiring an additional 4,863 shares in the last quarter. Raymond James Financial Services Advisors Inc. purchased a new stake in shares of Calithera Biosciences in the first quarter valued at about $117,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Calithera Biosciences in the first quarter valued at about $211,000. 71.91% of the stock is currently owned by institutional investors.
Calithera Biosciences (CALA) traded down 0.66% during trading on Friday, reaching $15.05. 1,008,078 shares of the company’s stock traded hands. The company’s market cap is $533.91 million. Calithera Biosciences has a 12-month low of $2.20 and a 12-month high of $20.05. The company has a 50 day moving average price of $15.06 and a 200-day moving average price of $14.01.
Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.14. The firm had revenue of $7.26 million during the quarter, compared to analyst estimates of $4.80 million. On average, equities research analysts forecast that Calithera Biosciences will post ($0.83) EPS for the current fiscal year.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.